Incyte (INCY) Prepaid Assets (2010 - 2026)
Incyte posted quarterly Prepaid Assets of $301.3 million for Q1 2026, up 42.36% year-on-year from $211.7 million in Q1 2025, and down 5.2% on a QoQ basis from $317.8 million in Q4 2025.
Incyte (INCY) has 17 years of Prepaid Assets data on file, last reported at $301.3 million in Q1 2026.
- For the quarter ending Q1 2026, Prepaid Assets rose 42.36% year-over-year to $301.3 million; the trailing twelve-month figure through Mar 2026 stood at $301.3 million (up 42.36% YoY), and the FY2025 full-year result was $317.8 million, up 88.16% from the prior year.
- Prepaid Assets for Q1 2026 stood at $301.3 million, down from $317.8 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $368.7 million in Q3 2025 and bottomed at $146.1 million in Q1 2022.
- The 5-year median for Prepaid Assets is $189.2 million (2024), against an average of $214.2 million.
- The widest annual swing landed in 2022, when Prepaid Assets surged 98.76%; it then slipped 7.61% in 2024.
- A 5-year view of Prepaid Assets shows it stood at $167.0 million in 2022, then increased by 9.47% to $182.8 million in 2023, then decreased by 7.61% to $168.9 million in 2024, then surged by 88.16% to $317.8 million in 2025, then retreated by 5.2% to $301.3 million in 2026.
- The last three Prepaid Assets figures came in at $301.3 million (Q1 2026), $317.8 million (Q4 2025), and $368.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 301.31 Mn |
| Dec 31, 2025 | 317.83 Mn |
| Sep 30, 2025 | 368.73 Mn |
| Jun 30, 2025 | 295.65 Mn |
| Mar 31, 2025 | 211.65 Mn |
| Dec 31, 2024 | 168.91 Mn |
| Sep 30, 2024 | 205.13 Mn |
| Jun 30, 2024 | 207.96 Mn |
| Mar 31, 2024 | 189.24 Mn |
| Dec 31, 2023 | 182.83 Mn |
| Sep 30, 2023 | 171.75 Mn |
| Jun 30, 2023 | 167.14 Mn |
| Mar 31, 2023 | 194.26 Mn |
| Dec 31, 2022 | 167.01 Mn |
| Sep 30, 2022 | 179.93 Mn |
| Jun 30, 2022 | 165.95 Mn |
| Mar 31, 2022 | 146.13 Mn |
| Dec 31, 2021 | 126.28 Mn |
| Sep 30, 2021 | 101.73 Mn |
| Jun 30, 2021 | 84.25 Mn |
| Mar 31, 2021 | 73.52 Mn |
| Dec 31, 2020 | 60.10 Mn |
| Sep 30, 2020 | 51.43 Mn |
| Jun 30, 2020 | 51.55 Mn |
| Mar 31, 2020 | 48.08 Mn |
| Dec 31, 2019 | 43.73 Mn |
| Jun 30, 2019 | 53.56 Mn |
| Mar 31, 2019 | 72.27 Mn |
| Dec 31, 2018 | 79.37 Mn |
| Sep 30, 2018 | 71.32 Mn |
| Jun 30, 2018 | 77.52 Mn |
| Mar 31, 2018 | 73.67 Mn |
| Dec 31, 2017 | 62.43 Mn |
| Sep 30, 2017 | 58.33 Mn |
| Jun 30, 2017 | 63.75 Mn |
| Mar 31, 2017 | 58.28 Mn |
| Dec 31, 2016 | 32.77 Mn |
| Sep 30, 2016 | 34.46 Mn |
| Jun 30, 2016 | 27.31 Mn |
| Mar 31, 2016 | 21.81 Mn |
| Dec 31, 2015 | 17.84 Mn |
| Sep 30, 2015 | 23.25 Mn |
| Jun 30, 2015 | 20.26 Mn |
| Mar 31, 2015 | 28.18 Mn |
| Dec 31, 2014 | 20.52 Mn |
| Sep 30, 2014 | 18.98 Mn |
| Jun 30, 2014 | 19.27 Mn |
| Mar 31, 2014 | 13.68 Mn |
| Dec 31, 2013 | 9.62 Mn |
| Sep 30, 2013 | 9.01 Mn |
| Jun 30, 2013 | 8.26 Mn |
| Mar 31, 2013 | 10.70 Mn |
| Dec 31, 2012 | 9.87 Mn |
| Sep 30, 2012 | 8.90 Mn |
| Jun 30, 2012 | 8.82 Mn |
| Mar 31, 2012 | 7.45 Mn |
| Dec 31, 2011 | 7.48 Mn |
| Sep 30, 2011 | 7.98 Mn |
| Jun 30, 2011 | 6.45 Mn |
| Mar 31, 2011 | 6.77 Mn |
| Dec 31, 2010 | 6.60 Mn |